Published in J Clin Pharm Ther on June 01, 2008
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica (2010) 1.49
The chemistry of isoindole natural products. Beilstein J Org Chem (2013) 0.87
Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res (2010) 0.80
Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. Ther Adv Drug Saf (2012) 0.78
Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma. P T (2016) 0.75
Lenalidomide-induced diffuse alveolar hemorrhage. Lung India (2014) 0.75
Radical-mediated dehydrative preparation of cyclic imides using (NH4)2S2O8-DMSO: application to the synthesis of vernakalant. Beilstein J Org Chem (2015) 0.75
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2011) 3.07
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia (2006) 1.83
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
P53 deletion is not a frequent event in multiple myeloma. Br J Haematol (1999) 1.57
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res (1999) 1.55
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Interferon alpha-2b therapy in refractory adult chronic thrombocytopenic purpura. Br J Haematol (1991) 1.39
Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood (1995) 1.39
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. Cancer Res (1999) 1.23
Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. Blood (1999) 1.16
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol (1998) 1.12
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res (1998) 1.09
POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia (1997) 1.09
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant (2001) 1.06
p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood (2001) 1.06
Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol (1996) 1.05
Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum (1993) 1.02
[POEMS syndrome]. Rev Med Interne (1997) 1.02
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer (1999) 1.01
Role of early splenectomy in malignant lymphomas with prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases. Cancer (1993) 0.99
Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol (1994) 0.98
patients with the description of a new scoring system and its validation on 253 other patients. Blood (2000) 0.98
Rare occurrence of P53 gene mutations in multiple myeloma. Br J Haematol (1992) 0.95
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia (2004) 0.93
Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant (2003) 0.92
Acute monocytic leukaemia in adults: treatment and prognosis in 99 cases. Br J Haematol (1990) 0.92
Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia (1995) 0.91
Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit (2007) 0.88
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J Clin Pharm Ther (2011) 0.88
Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur J Haematol (1996) 0.85
The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leuk Lymphoma (1995) 0.84
Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant (2003) 0.83
[Preventing medication errors during anaesthesia. Recommendations]. Ann Fr Anesth Reanim (2007) 0.82
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant (2005) 0.82
Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol (2001) 0.81
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma. J Clin Immunol (1993) 0.81
CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol (1995) 0.81
Double-intensive therapy in high-risk multiple myeloma. Blood (1992) 0.81
Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl (2000) 0.80
Thalidomide in patients with advanced multiple myeloma. Hematol J (2000) 0.80
Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Am J Med (1996) 0.80
Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases. Leukemia (1999) 0.79
Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum Gene Ther (1999) 0.79
Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant. Cancer Genet Cytogenet (1998) 0.79
Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM) Leukemia (1999) 0.78
Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. Br J Haematol (1998) 0.78
Involvement of macrophages in lethal forms of graft-versus-host disease. Lancet (1995) 0.78
Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate (2001) 0.78
Early paternity and relapse after bone marrow transplantation. Am J Hematol (1993) 0.78
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia (2012) 0.77
Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol (1989) 0.77
Significance of circulating plasma cells in multiple myeloma. Leuk Lymphoma (1994) 0.77
Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML. Leukemia (2005) 0.77
[Thalidomide: mechanisms of action and new insights in hematology]. Rev Med Interne (2005) 0.77
Pseudomembranous conjunctivitis following bone marrow transplantation: immunopathological and ultrastructural study of one case. Hum Pathol (1996) 0.77
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol (1997) 0.77
[Study of meta-trajectories of CD4 cells count from taxonomy in the antiretroviral response of efavirenz-based regimen with naive symptomatic patients in Abidjan]. Ann Pharm Fr (2010) 0.77
Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. J Clin Pharm Ther (2014) 0.77
Cytomegalovirus expression in minor salivary glands and chronic graft-versus-host disease. Bone Marrow Transplant (1994) 0.76
Acute flare-up of conjunctival graft-versus-host disease with eosinophil infiltration in a patient with chronic graft-versus-host disease. Leuk Lymphoma (2002) 0.76
Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant (1999) 0.76
Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol (1995) 0.76
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol (1996) 0.76
Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. Cancer Genet Cytogenet (1994) 0.76
Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist? Leukemia (1999) 0.76
Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis. Ther Drug Monit (1999) 0.76
[Bioavailability and bone toxicity of barium chloride by chronic administration in rats]. Ann Pharm Fr (1996) 0.75
Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: report of two patients. Am J Hematol (1992) 0.75
Induction of apoptosis by all-trans retinoic acid in the human myeloma cell line RPMI 8226 and negative regulation of some of its typical morphological features by dexamethasone. Cell Death Differ (1999) 0.75
Soluble CD16 in plasma cell dyscrasias. Leuk Lymphoma (1999) 0.75
Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation. Bone Marrow Transplant (1991) 0.75
[Cutaneous manifestations of light chain deposition disease (Randall's syndrome)]. Ann Dermatol Venereol (1992) 0.75
[Malignant lymphoma of the testicles]. Rev Med Interne (1994) 0.75
Allogeneic bone marrow transplantation in multiple myeloma using HLA-compatible sibling donors--an EBMT Registry Study. Bone Marrow Transplant (1991) 0.75
Involvement of peripheral blood cells in multiple myeloma: chromosome changes are the rule within circulating plasma cells but not within B lymphocytes. Leukemia (1997) 0.75
VIM3-ARA C: an effective salvage regimen in refractory or recurrent aggressive non Hodgkin's lymphoma. A report on 18 cases. Hematol Oncol (1992) 0.75
Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. Leuk Lymphoma (1991) 0.75
[Congenital asplenia, a differential diagnosis of essential thrombocythemia]. Presse Med (1993) 0.75
[Analysis of opiates in the urine of children with gas chromatography coupled to mass spectrometry]. J Pharm Belg (1995) 0.75
[Correlation between the serum level of soluble CD16 and the staging of myeloma: study of 214 serums]. Rev Med Interne (1993) 0.75
[Mediastinal adenopathies and myeloma]. Rev Med Interne (1992) 0.75
Sequential high dose intravenous immunoglobulin for demyelinating neuropathy associated with monoclonal IgM gammapathy. Eur J Med (1992) 0.75
Acute monocytic leukemia with (8;22)(p11;q13) translocation. Involvement of 8p11 as in classical t(8;16)(p11;p13). Cancer Genet Cytogenet (1992) 0.75
[Granulocytic sarcoma. Apropos of a case]. Ann Radiol (Paris) (1991) 0.75
Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells. Leukemia (1998) 0.75
Should all CMV infections after bone marrow transplantation be treated? Bone Marrow Transplant (1991) 0.75
[Amyloidosis AL of the breast in an ileal carcinoid tumor]. Ann Pathol (1997) 0.75